Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CDSCO denies approval...

    CDSCO denies approval for Akums Acid reflux FDC in Capsule form

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-05-08T10:15:22+05:30  |  Updated On 16 Aug 2021 3:04 PM IST

    New Delhi: In order to expand its portfolio, Akum Drugs & Pharmaceuticals Ltd. presented before the Subject Experts Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) to seek permission for Fixed Dose Combination (FDC) of Rabeprazole Sodium and Levosulpiride in a capsule dosage form. However, the committee turned down the proposal stating that the capsule dosage form is not required as it will not have any added advantage.


    Akums Drugs brought an in-depth presentation before the SEC Committee for the FDC of Levosulpiride in the strength of 75 mg and Rabeprazole Sodium in the strength of 40 mg capsules.


    FDC of Levosulpiride and Rabeprazole is indicated for the treatment of gastroesophageal reflux disease (acid reflux), intestinal ulcers and irritable bowel syndrome.


    Levosulpiride is a prokinetic which works by increasing the release of acetylcholine. This increases the movement of the stomach and intestines and prevents reflux while Rabeprazole is a proton pump inhibitor (PPI). It works by reducing the amount of acid in the stomach which helps in the relief of acid-related indigestion and ulcers.


    Presently, a combination of Rabeprazole Sodium and Levosulpiride is available in the market in various strengths under different brand names including a generic combination of Rabeprazole 20mg and Levosulpiride(SR) 75mg under the brand name Rabekind Plus (20mg/75mg). Rabekind Plus is manufactured by Mankind Pharma while another notable drugmaker Zydus Cadila manufactures the same under the brand name Happi-L (20mg/75mg).


    Akums' recent proposal to manufacture the said drug in capsule form was rejected by the committee. The committee noted that FDC of Rabeprazole 40mg (Enteric coated) + Levosulpiride 75 mg (sustained release) tablet is already declared rationale by Kokate committee. However, the present proposal is with respect to the capsule dosage form of the same FDC which contains individual tablets of both the drugs.


    Deliberating the matter, the committee said, "The applied dosage form of the FDC i.e. capsule dosage form is not required as it will not have any added advantage. Hence the committee didn't recommend for approval."


    Also Read: NPPA fixes retail price of 20 drugs including FDCs for Blood pressure control, dual antiplatelet

    acidityAkumsAkums DrugscapsuleCDSCOCentral Drugs Standard Control OrganizationFDCFixed Dose Combinationgasgastroesophagealgeneric combinationHappi-LKokate committeeLevosulpirideMankind PharmaPPIproton pump inhibitorRabekind PlusRabeprazole SodiumSEC CommitteeTabletsZydus Cadila

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok